Table 1.
Baseline characteristics of studies included in the network meta-analysis of patients with wild-type advanced non-small cell lung cancer.
| Study name (year) | Phase | Population | Sample size | Median age | Male/Female | Intervention arm | Control arm |
|---|---|---|---|---|---|---|---|
| SICI | |||||||
| KEYNOTE 024 (2016/2019) | III | squ/non-squ PD-L1≥50% | 154/151 | 65/66 | 187/118 | PEM | CT |
| KEYNOTE 042 (2019) | III | squ/non-squ PD-L1≥1% | 637/637 | 63/63 | 902/372 | PEM | CT |
| IMpower 110 (2019) | III | squ/non-squ PD-L1≥1% | 277/277 | NG/NG | 389/165 | ATE | CT |
| MYSTIC (2020) | III | squ/non-squ | 374/372 | 65/64 | 506/240 | DUR | CT |
| CheckMate 026 (2017) | III | squ/non-squ PD-L1≥1% | 271/270 | 63/65 | 332/209 | NIV | CT |
| CheckMate 227 part1 (2019) | III | squ/non-squ PD-L1≥1% | 396/397 | 64/64 | 532/261 | NIV | CT |
| EMPOWER-LUNG1 (2020) | III | squ/non-squ | 356/354 | 63/64 | 606/104 | CEM | CT |
| SICI+CT | |||||||
| KEYNOTE 021G (2016/2019) | II | non-squ | 60/63 | 63/63 | 48/75 | PEM+CT | CT+Mpem |
| KEYNOTE 189 (2018/2020) | III | non-squ | 410/206 | 65/64 | 363/253 | PEM+CT | CT+Mpem |
| KEYNOTE 407 (2018/2020) | III | squ | 278/281 | 65/65 | 455/104 | PEM+CT | CT |
| IMpower 130 (2019) | III | non-squ | 483/240 | 64/65 | 415/308 | ATE+CT | CT |
| IMpower 132 (2018/2020) | III | non-squ | 292/286 | 64/63 | 384/194 | ATE+CT | CT+Mpem |
| IMpower 131 (2020) | III | squ | 343/340 | 65/65 | 557/126 | ATE+CT | CT |
| CAMEL (2019) | III | non-squ | 205/207 | 59/61 | 295/117 | CAM+CT | CT |
| ORIENT-12 (2020) | III | squ | 179/178 | 64/62 | 327/50 | SIN+CT | CT |
| ORIENT-11 (2020) | III | non-squ | 266/131 | 61/61 | 303/94 | SIN+CT | CT |
| CheckMate 227 part1 (2019) | III | squ/non-squ PD-L1<1% | 177/186 | 64/64 | 255/108 | NIV+CT | CT |
| CheckMate 227 part2 (2019) | III | squ/non-squ | 377/378 | 63/64 | 528/227 | NIV+CT | CT |
| Lynch (2012) | II | squ/non-squ | 68/66 | 61/62 | 98/36 | IPI+CT | CT |
| Govindan (2017) | III | squ | 388/361 | 64/64 | 635/114 | IPI+CT | CT |
| DICI | |||||||
| MYSTIC (2020) | III | squ/non-squ | 372/372 | 66/64 | 516/228 | DUR+TRE | CT |
| CheckMate 227 part1 (2019) | III | squ/non-squ PD-L1≥1% | 396/397 | 64/64 | 515/278 | NIV+IPI | CT |
| CheckMate 227 part1 (2019) | III | squ/non-squ PD-L1<1% | 187/186 | 63/64 | 263/110 | NIV+IPI | CT |
| DICI+CT | |||||||
| CheckMate 9LA (2020) | III | squ/non-squ | 361/358 | 65/65 | 503/216 | NIV+IPI+CT | CT |
| Others | |||||||
| CCTG BR.34 (2020) | III | squ/non-squ | 151/150 | 65/63 | 162/139 | DUR+TRE+CT | DUR+TRE |
Data are expressed as intervention/control unless indicated otherwise.
Squ, squamous; Non-squ, non-squamous; NG, not given; PEM, pembrolizumab; CEM, cemiplimab; SIN, sintilimab; ATE, atezolizumab; NIV, nivolumab; DUR, durvalumab; TRE, tremelimumab; CAM, camrelizumab; IPI, ipilimumab; CT, chemotherapy; CT+Mpem, CT followed by maintenance with pemetrexed.